Summary of Clinical Use

Preliminary evidence of clinical efficacy in a small number of patients with highly refractory, heavily pretreated B-cell non-Hodgkin lymphoma has been reported [4]- see NCT00614042. A Phase 1b study of TRU-016 plus other biological or small molecule chemotherapeutic drugs (NCT01644253) is under way (May 2018).

Mechanism Of Action and Pharmacodynamic Effects

Otlertuzumab induces apoptosis directly via binding to the CD37 molecule, utilising a mechanism that is caspase-independent [3,8]. Preclinical in vitro and in vivo studies show that otlertuzumab mediates apoptosis and Fc‐dependent cellular toxicity against primary CLL and NHL cells [8].

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT00614042	Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma	Phase 1 Interventional	Aptevo Therapeutics
NCT01644253	Phase 1b Safety and Efficacy Study of TRU-016	Phase 1 Interventional	Aptevo Therapeutics